ArticleFrontiers in oncology2021

Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations.

Jiatao Liao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.